You are here: Industry Insights > Amgen

News List

Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation worldpharmanews
July 19, 2017
Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders.
Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation worldpharmanews
July 19, 2017
Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders.
FDA refuses approval of Amgen osteoporosis drug pharmafile
July 18, 2017
Amgen and its development partner UCB have announced that the FDA has issued a complete response letter for the biologics license application for their osteoporosis drug Evenity (romosozumab), refusing to approve the treatment for use in postmenopausal fe
Amgen’s Blincyto wins full US approval Pharmatimes
July 17, 2017
Amgen’s Blincyto has been issued a full approval in the US as a treatment for adults and children with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
Amgen and QB3@953 announce winners of The Amgen Golden Ticket worldpharmanews
July 13, 2017
Amgen (NASDAQ: AMGN) and QB3@953 today announced that Darmiyan and Enable Biosciences have won the Amgen Golden Ticket at QB3@953. Each company receives one year of lab space at the QB3@953 life sciences incubator
Amgen and QB3@953 announce winners of The Amgen Golden Ticket worldpharmanews
July 12, 2017
Amgen (NASDAQ: AMGN) and QB3@953 today announced that Darmiyan and Enable Biosciences have won the Amgen Golden Ticket at QB3@953. Each company receives one year of lab space at the QB3@953 life sciences incubator...
Amgen’s uncontrolled LDL cholesterol lowering drug available in Singapore biospectrumasia
July 04, 2017
Amgen's breakthrough treatment will help patients significantly reduce LDL cholesterol levels.
FDA accepts Amgen's sBLA to expand indication for Xgeva to include multiple myeloma patients cphi-online
June 23, 2017
Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumours and is the number one prescribed agent by oncologists for this indication in the US.
Amgen’s myeloma treatment Kyprolis gains NICE approval pharmaphorum
June 14, 2017
NICE has recommended Amgen’s multiple myeloma treatment Kyprolis, a next generation drug which has shown itself superior to Janssen’s standard treatment Velcade.
Amgen showcases a legacy of science, innovation and collaboration in Cambridge worldpharmanews
June 05, 2017
Now one of the world's leading independent biotechnology companies, Amgen has expanded its presence in Cambridge and today hosted members of the Massachusetts life sciences community...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page